Inhibition of ILT4 can prevent TAM-mediated immunosuppression and improve the efficacy of treatment with a PD-L1 inhibitor in NSCLC patients with EGFR mutation. The gene discussed is LILRB2; the disease is non-small cell lung carcinoma.